Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2013

View Archived Issues

Lithium carbonate evaluated in phase II/III trial in Machado-Joseph disease

Serum ferritin levels predict response to chemotherapy in AML

Germline DICER1 gene mutations common in pleuropulmonary blastoma

FDA recommends additional trial of StemEx

Fibrocell Science and Intrexon expand strategic collaboration

Bayer completes acquisition of German company

Bioventus acquires rights to Pfizer's bone morphogenetic protein portfolio

FDA places clinical hold on sovaprevir

Insmed updates progress of Arikace programs

Alnylam reports phase II data for ALN-TTR02

Pharming and Shanghai Institute of Pharmaceutical Industry form strategic collaboration

SCRI and AstraZeneca form personalized medicine partnership

AmpliPhi BioSciences signs global agreement with U.S. Army

TransTech Pharma meets with FDA for TTP-488

Galapagos begins phase I trial of GLPG-1205

Vasopressin precursor levels assessed in Legionnaires' disease and other pneumonias

In vitro and in vivo anti-HIV activity of a novel HIV-1 splicing inhibitor

Benefit of MAO inhibitors in Parkinson's disease may be due to effects on CNP

Dr. Reddy's Laboratories patents new Trk-A inhibitors

Novel sodium channel blockers disclosed by Pfizer

Ariad obtains European approval for use of Iclusig in two leukemia indications

Novel renin inhibitors divulged by Sun Pharma Advanced Research

Small-molecule angiogenesis and proliferation inhibitor targets multiple cancer pathways

FDA grants orphan drug status to Tromplate and carbamazepine

FDA grants priority review for obinutuzumab BLA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...